TETERBORO, N.J., Oct 17, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quest
Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of
diagnostic testing, information and services, announced that for the third
quarter ended September 30, 2002, net income increased to $87 million, or $0.87
per diluted share, from $50 million, or $0.51 per diluted share, in the third
quarter of 2001. Earnings per diluted share increased 45% from $0.60 in 2001,
adjusted for the required change in goodwill accounting (SFAS 142).
Third quarter 2002 earnings include a $3.8 million pre-tax gain on an investment
and a $1.5 million pre-tax charge associated with the integration of American
Medical Laboratories (AML), which combined to contribute earnings of $0.01 per
share.
Third quarter revenues of $1.1 billion grew 17.2% over the prior year level and
reflect the acquisition of AML, which was completed on April 1, 2002. Clinical
testing volume, measured by the number of requisitions, increased 13.7% compared
to the prior year, or 5% on a pro forma basis, assuming that AML had been part
of Quest Diagnostics since January 1, 2001. Revenue per requisition increased
2.9% compared to the prior year.
"Strong performance was driven by our continued focus on generating profitable
top-line growth and the benefits of our Six Sigma quality and standardization
initiatives," said Kenneth W. Freeman, Chairman and Chief Executive Officer. "We
continue to focus on effective execution, and the fundamentals of our business
remain sound."
Earnings before interest, taxes, depreciation and amortization (EBITDA), were
$192 million, or 18.2% of revenues, compared to $142 million, or 15.7% of
revenues, in 2001. Bad debt expense improved to 5.1% of revenues, compared to
6.1% for the prior year period. Days sales outstanding improved to 51 days,
compared to 52 days at the end of the second quarter. Capital expenditures
totaled $35 million for the quarter.
For the first nine months of 2002, net income increased to $240 million from
$137 million before special items in 2001. Earnings per diluted share were
$2.41, compared to $1.40 before special items in the prior year. The special
items represented an extraordinary loss and a special charge associated with the
company's debt refinancing in the second quarter of 2001. Earnings per diluted
share increased 43% from $1.68 in 2001, adjusted for the required change in
goodwill accounting and the special items incurred in 2001. Revenues increased
13.1% to $3.1 billion. EBITDA was $543 million, or 17.7% of revenues, compared
to $413 million, or 15.2% of revenues, adjusted for special items, in 2001.
Capital expenditures were $118 million.
For the fourth quarter of 2002, the company is comfortable with the current
consensus of analyst earnings expectations of $0.78 per diluted share, as
published by Thomson First Call. Revenues are expected to grow approximately 14%
compared to the prior year. Volume is expected to grow between 12% and 13%, or
approximately 4% on a pro forma basis, assuming that AML had been part of Quest
Diagnostics since January 1, 2001. Revenue per requisition is expected to
increase between 2% and 3%. EBITDA is expected to exceed 17% of revenues. For
the full year 2002, earnings per diluted share are expected to increase by
approximately 40%, excluding the benefit from the goodwill accounting change and
special items in 2001. Estimates exclude the impact of the planned acquisition
of Unilab, which the company hopes to complete in the fourth quarter.
Quest Diagnostics' third quarter conference call will take place on October 18
at 8:00 A.M. Eastern Time. To hear a simulcast of the call over the Internet, or
a replay, registered analysts may access StreetEvents at: www.streetevents.com
and all others may access the Quest Diagnostics website at:
www.questdiagnostics.com. In addition, a replay of the call will also be
available from 10 A.M. on October 18 through 5 P.M. on November 14 to investors
in the U.S. by dialing 800-216-3090. Investors outside the U.S. may dial
402-220-3857. No password is required for either number.
Quest Diagnostics Incorporated is the nation's leading provider of diagnostic
testing, information and services, providing insights that enable physicians,
hospitals, managed care organizations and other healthcare professionals to make
decisions to improve health. The company offers patients and physicians the
broadest access to diagnostic laboratory services through its national network
of laboratories and patient service centers. Quest Diagnostics is the leading
provider of esoteric testing, including gene-based medical testing, and empowers
healthcare organizations and clinicians with state-of-the-art connectivity
solutions that improve practice management. Additional company information can
be found on the Internet at: www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking statements
involve risks and uncertainties that could cause actual results and outcomes to
be materially different. Certain of these risks and uncertainties may include,
but are not limited to, unanticipated expenditures, changing relationships with
customers, suppliers and strategic partners, conditions of the economy and other
factors described in the Quest Diagnostics Incorporated 2001 Form 10-K and
subsequent filings.
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2002 and 2001
(in millions, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001
Net revenues $1,058.7 $903.2 $3,074.3 $2,717.3
Costs and expenses:
Cost of services 625.1 535.6 1,813.1 1,614.0
Selling, general
and administrative 272.6 251.0 807.8 760.3
Interest expense, net 13.4 14.8 41.0 58.0
Amortization of
intangible assets 2.0 11.4 6.2 34.7
Provision for
special charge -- -- -- 6.0
Minority share of income 3.7 2.9 11.5 6.8
Other, net (4.2) (2.4) (10.4) (3.6)
Total 912.6 813.3 2,669.2 2,476.2
Income before taxes
and extraordinary loss 146.1 89.9 405.1 241.1
Income tax expense 59.5 39.8 164.6 108.1
Income before
extraordinary loss 86.6 50.1 240.5 133.0
Extraordinary loss,
net of taxes -- -- -- (21.6)
Net income $86.6 $50.1 $240.5 $111.4
Income before
extraordinary loss
and special charge $86.6 $50.1 $240.5 $136.6
Basic earnings per common share:
Income before
extraordinary loss $0.89 $0.54 $2.50 $1.43
Net income 0.89 0.54 2.50 1.20
Income before
extraordinary loss
and special charge 0.89 0.54 2.50 1.47
Weighted average
common shares
outstanding - basic 96.9 93.4 96.2 92.6
Diluted earnings per common share:
Income before
extraordinary loss $0.87 $0.51 $2.41 $1.37
Net income 0.87 0.51 2.41 1.14
Income before
extraordinary loss
and special charge 0.87 0.51 2.41 1.40
Weighted average
common shares
outstanding - diluted 99.7 98.0 99.8 97.3
EBITDA $192.4 $141.8 $542.8 $413.0
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
September 30, 2002 and December 31, 2001
(in millions, except per share data)
September 30, December 31,
2002 2001
Assets
Current assets:
Cash and cash equivalents $113.8 $122.3
Accounts receivable, net 576.5 508.3
Inventories 59.0 49.9
Deferred income taxes 139.8 157.6
Prepaid expenses and other current assets 41.0 38.4
Total current assets 930.1 876.5
Property, plant and equipment, net 571.5 508.6
Goodwill, net 1,789.4 1,351.1
Intangible assets, net 22.3 28.0
Deferred income taxes 53.1 52.7
Other assets 99.3 113.7
Total assets $3,465.7 $2,930.6
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $610.4 $657.2
Short-term borrowings and current
portion of long-term debt 251.1 1.4
Total current liabilities 861.5 658.6
Long-term debt 796.8 820.3
Other liabilities 129.7 115.7
Common stockholders' equity:
Common stock, par value $0.01 per share;
300 shares authorized; 97.7 and 96.0 shares
issued and outstanding at September 30, 2002
and December 31, 2001, respectively 1.0 1.0
Additional paid in capital 1,807.5 1,714.7
Accumulated deficit (122.5) (362.9)
Unearned compensation (5.5) (13.3)
Accumulated other comprehensive loss (2.8) (3.5)
Total common stockholders' equity 1,677.7 1,336.0
Total liabilities and stockholders' equity $3,465.7 $2,930.6
Notes to Financial Tables
1) Depreciation expense totaled $30.9 million and $25.7 million for the
three months ended September 30, 2002 and 2001, respectively, and $90.5
million and $73.3 million for the nine months ended September 30, 2002
and 2001, respectively.
2) Net income per common share is computed by dividing net income less
dividends on preferred stock (approximately $30 thousand per quarter in
2001) by the weighted average number of common shares outstanding.
Potentially dilutive common shares primarily represent stock options.
During the fourth quarter of 2001, the Company redeemed all of the then
issued and outstanding shares of preferred stock.
The following table presents net income and basic and diluted earnings
per common share, had the Company elected to recognize compensation
cost based on the fair value at the grant dates for stock option awards
and discounts granted for stock purchases under the Company's Employee
Stock Purchase Plan, consistent with the method prescribed by Statement
of Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation" ("SFAS 123"):
Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001
(in millions, except per share data)
Net income:
Net income $86.6 $50.1 $240.5 $111.4
Impact of recognizing
compensation cost
pursuant to
provisions of SFAS 123 (10.2) (7.1) (28.2) (17.1)
Net income, adjusted
for impact of SFAS 123 $76.4 $43.0 $212.3 $94.3
Basic earnings
per common share:
Net income $0.89 $0.54 $2.50 $1.20
Impact of recognizing
compensation cost
pursuant to provisions
of SFAS 123 (0.10) (0.08) (0.29) (0.18)
Net income, adjusted
for impact of SFAS 123 $0.79 $0.46 $2.21 $1.02
Diluted earnings
per common share:
Net income $0.87 $0.51 $2.41 $1.14
Impact of recognizing
compensation cost
pursuant to provisions
of SFAS 123 (0.10) (0.07) (0.28) (0.17)
Net income, adjusted
for impact of SFAS 123 $0.77 $0.44 $2.13 $0.97
The fair value of each option grant was estimated on the date of grant using the
Black-Scholes option-pricing model with the following weighted average
assumptions:
Three Months Ended Nine Months Ended
September 30, September 30,
2002 2001 2002 2001
Dividend yield 0.0% 0.0% 0.0% 0.0%
Risk-free interest rate 3.8% 5.1% 4.2% 5.2%
Expected volatility 46.2% 47.7% 45.2% 47.7%
Expected holding
period, in years 5 5 5 5
3) Other, net, which represents income for each of the periods presented,
includes equity earnings from our unconsolidated joint ventures and
miscellaneous gains and losses. For the three and nine months ended
September 30, 2002, other, net includes a $3.8 million gain on an
investment and a $1.5 million charge associated with the integration of
AML. For the nine months ended September 30, 2001, other, net includes
the net impact of writing off $7.0 million of impaired assets and a
$6.3 million gain on the sale of an investment.
4) During the second quarter of 2001, the Company refinanced the majority
of its indebtedness. The extraordinary loss of $36.0 million ($21.6
million, net of tax) represents the write-off of deferred financing
costs, and tender premiums paid in connection with extinguishing the
debt that was refinanced.
5) In conjunction with the Company's debt refinancing during the second
quarter of 2001, the Company recorded a special charge of $6.0 million
($3.6 million, net of tax) representing the costs to settle existing
interest rate swap agreements on its debt, which was refinanced.
6) EBITDA represents income before net interest expense, income taxes,
depreciation and amortization, before special items in 2001. The
special items represented the extraordinary loss and the special charge
associated with the Company's debt refinancing in the second quarter of
2001.
7) In July 2001, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 142, "Goodwill and Other
Intangibles" ("SFAS 142"), which the Company adopted on January 1,
2002. The following table presents net income and basic and diluted
earnings per common share data adjusted to exclude the amortization of
goodwill, assuming that SFAS 142 had been in effect for the periods
presented:
Three Months Nine Months
Ended Ended
September 30, September 30,
2001 2001
(in millions, except per share data)
Net income:
Adjusted income before extraordinary loss $59.0 $160.1
Adjusted net income 59.0 138.4
Adjusted income before extraordinary
loss and special charge 59.0 163.6
Basic earnings per common share:
Adjusted income before extraordinary loss $0.63 $1.73
Adjusted net income 0.63 1.49
Adjusted income before extraordinary loss
and special charge 0.63 1.77
Diluted earnings per common share:
Adjusted income before extraordinary loss $0.60 $1.64
Adjusted net income 0.60 1.42
Adjusted income before extraordinary loss
and special charge 0.60 1.68
SOURCE Quest Diagnostics Incorporated
CONTACT:
Laure Park, Investors, +1-201-393-5030, or Gary Samuels, Media,
+1-201-393-5700, both of Quest Diagnostics Incorporated
URL: http://www.questdiagnostics.com
Copyright (C) 2002 PR Newswire. All rights reserved.